Sonoma Pharmaceuticals, Inc.
SNOA · NASDAQ
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Revenue | $14 | $13 | $13 | $13 |
| % Growth | 12.2% | -4% | 5.1% | – |
| Cost of Goods Sold | $9 | $8 | $9 | $9 |
| Gross Profit | $5 | $5 | $4 | $4 |
| % Margin | 38.2% | 37.3% | 33.7% | 31.6% |
| R&D Expenses | $2 | $2 | $0 | $0 |
| G&A Expenses | $7 | $0 | $0 | $0 |
| SG&A Expenses | $7 | $8 | $9 | $10 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $9 | $9 | $9 | $10 |
| Operating Income | -$4 | -$5 | -$5 | -$6 |
| % Margin | -26% | -36.9% | -34.4% | -46.6% |
| Other Income/Exp. Net | $1 | -$0 | -$1 | $0 |
| Pre-Tax Income | -$3 | -$5 | -$5 | -$5 |
| Tax Expense | $1 | -$0 | -$0 | -$0 |
| Net Income | -$3 | -$5 | -$5 | -$5 |
| % Margin | -24.2% | -38% | -38.8% | -40.3% |
| EPS | -2.79 | -5.32 | -15.18 | -19.17 |
| % Growth | 47.6% | 65% | 20.8% | – |
| EPS Diluted | -2.79 | -5.32 | -15.18 | -19.17 |
| Weighted Avg Shares Out | 1 | 1 | 0 | 0 |
| Weighted Avg Shares Out Dil | 1 | 1 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$4 | -$5 | -$4 | -$6 |
| % Margin | -25% | -35.5% | -33.5% | -45.1% |